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Plasma cells (PCs) have a heterogeneous phenotype in humans. While bone marrow PCs
are CD20−CD138+, tonsil PCs are CD20+CD138+/− and peripheral plasmablasts (PBs)
are CD20−CD138−. In vitro, PCs are mainly generated by the activation of CD27+ mem-
ory B-cells through transient stimulation of CD40, and their phenotype appears similar
to that of bone marrow PCs. While CD20 expression is lost at the plasmablastic stage,
CD138 expression appears only at the PC stage. Thus, the CD20+CD138± phenotype of
tonsil PCs does not represent an intermediate stage in the differentiation of memory B-
cells into PCs. Because it has been previously shown that TLR9 activation was more able
than CD40 stimulation to induce the differentiation of IgM+ CD27+ B-cells, we wondered
whether TLR9 or CD40 stimulation would induce the same phenotype of PCs. Thus, we
compared the differentiation of CD27+ B-cells isolated from either the tonsils or periph-
eral blood and stimulated with either CD40L-expressing ﬁbroblasts or a TLR9 ligand, CpG
oligodeoxynucleotide (CpG ODN). We observed that CpG ODN mainly induced CD27+ B-
cell differentiation into CD20+CD38+CD138− PBs and CD20+CD38+CD138± PCs, which
appear similar to tonsil PCs. Removal of CpG ODN during differentiation induced a decrease
in the CD20+ plasmablastic population, and, conversely, stimulation of CD40L-induced pre-
plasmablasts with CpG ODN increased the population of CD20+CD38+ PBs. Analysis of
Ig secretion showed that CpG ODN induced increased IgM secretion compared to CD40L.
PCs from patients with multiple myeloma, the malignant counterpart of bone marrow PCs,
rarely express CD20. We show that CpG ODN did not induce or increase CD20 in nine
IgG or IgA myeloma cell lines. These data strongly suggest that CpG ODN mainly targets
CD27 IgM B-cells.+ +
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INTRODUCTION
Plasma cells (PCs) are terminally differentiated B-cells (Shapiro-
Shelef and Calame, 2005; De Vos et al., 2006; Moser et al., 2006;
Radbruch et al., 2006). Memory B-cells are activated in secondary
immune organs and differentiate into plasmablasts (PBs), which
migrate to inﬂamed tissues, lamina propria, and bone marrow,
where they differentiate into PCs (Arpin et al., 1997). Long-lived
PCs that are the source of protective antibodies are mainly located
within the bone marrow. PCs are found not only within bone
marrow but are also located within secondary immune organs
such as the spleen, lymph nodes, and tonsils. PCs in all organs
exhibit a shared phenotype, but some differences can be observed.
For example, tonsil PCs are CD20+ and CD138+/−, in contrast
to BM PCs that are CD20− but CD138++ (Pellat-Deceunynck
et al., 1994; Medina et al., 2002; Robillard et al., 2005). During
B-cell differentiation into PCs, CD20 expression is lost at the
Abbreviations: MFI, mean ﬂuorescence intensity; PB, plasmablast; PC, plasma cell;
prePB, pre-plasmablast.
plasmablastic stage andCD138upregulation occurs at the PC stage
(Jego et al., 2001). In vivo, expansions of non-malignant polyclonal
PBs and PCs are transiently observed in patients with IL-6 produc-
ing tumors or in the context of acute infections (Jego et al., 1999).
These PBs and PCs never express CD20 (Jego et al., 1999). PCs
from tonsil have been considered to be immature PCs, which can
leave the tonsil to migrate to the bone marrow. However, pheno-
typic studies of cytoplasmic Ig+ (cIg+) cells in the blood during
a secondary immune response have shown that cIg+ cells have
a phenotype typical for PBs, CD20−CD138−, making it unlikely
that tonsil PCs are the precursors to BM PCs or peripheral PBs
(Medina et al., 2002; Odendahl et al., 2005; Robillard et al., 2005).
Based on phenotype, the tonsil PCs appear to be different from
other types of PCs or PBs.
In vitro, PBs and PCs have been mainly obtained from
memory B-cells activated by CD40L (Arpin et al., 1995; Jego
et al., 2001). In this culture system, the PBs and PCs obtained
never expressed CD20. Microbial products activate B-cells, which
express a wide range of toll-like receptors (TLRs). Indeed, B-cells
express TLR9 and are strongly activated by TLR9 ligand, CpG
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oligodeoxynucleotides (CpG ODN). Bernasconi et al. (2002) have
reported that CpG ODN induce the proliferation and differentia-
tion of CD27+ B-cells into PCs and that CpG ODN, in contrast
to CD40L, strongly stimulate IgM+ B-cells. Thus, we wondered
whether the activation of CD27+ B-cells by two very different cul-
ture systems (CD40L or CpG ODN) would generate PBs and PCs
with similar or different features. Our data show that CpG ODN,
in contrast to CD40L, promote the generation of CD20+ PCs.
MATERIALS AND METHODS
ANTIBODIES AND REAGENTS
Anti-CD20-FITC, anti-CD38-APC, and IgG1-APC control were
purchased from BD Biosciences (Le Pont de Claix, France).
Anti-CD45-FITC, anti-CD138-PE, IgG1-FITC control, and IgG1-
PE control were purchased from Beckman Coulter (Roissy,
France). Blocking anti-CD40L mAb was purchased from Alexis
(Coger, Paris, France). The recombinant human cytokines IL2,
IL10, and IL15 were obtained from R&D (Minneapolis, MN,
USA). The TLR9 ligand, CpG phosphorothioated ODN (5-
0TCGTCGTTTTGTCGTTTTGTCGTT-30, CpG2006), was pur-
chased from InvivoGen (San Diego, CA, USA).
Antibodies against Bim (Abs) and actin (mAb) were purchased
from Millipore (Merck Serono, Lyon, France), anti-Mcl-1 Abs and
anti-caspase 3 mAb were purchased from Santa Cruz Biotechnol-
ogy (Tebu-Bio, Le Perray enYvelines, France), anti-Bcl-2 mAb was
purchased from Dako (Trappes, France), anti-p27 and anti-PCNA
mAbs were purchased from BD Pharmingen (BD Biosciences, Le
Pont deClaix, France), anti-p18mAbwas purchased fromCell Sig-
naling Technology (Ozyme, Saint-Quentin en Yvelines, France),
anti-Bcl-xL Abs were purchased from Transduction Laboratories
(BD Biosciences, Le Pont de Claix, France) and anti-survivin Abs
were purchased from R&D Systems Europe (Abingdon, UK).
GENERATION OF PLASMABLASTS AND PLASMA CELLS
Human cells were obtained from normal donors after informed
consent. Tonsils were obtained from children and teenagers
undergoing routine tonsillectomy. Following isolation by Ficoll–
Hypaque centrifugation and adherence, the lymphocytes were
cryopreserved. After thawing, the T cells were removed by sheep
rosetting (two rounds), and CD27+ B-cells were sorted (MACS,
Miltenyi Biotec, Germany), as previously described (Jego et al.,
2001; Geffroy-Luseau et al., 2008). Peripheral blood samples from
donor volunteers were provided by the French Blood Institute
(Etablissement Français du Sang, Nantes). After Ficoll–Hypaque
centrifugation and adherence, CD19+CD27+ B-cells were sorted
with the CD19 Multisort Kit (MACS, Miltenyi).
Generation of PBs and PCs by transient activation of CD40
was performed as initially described by Arpin et al. (1995), though
slightly modiﬁed (Arpin et al., 1997; Jego et al., 2001; Geffroy-
Luseau et al., 2008). Brieﬂy, CD27+ B-cells were incubated for
3 days (Day 3) over mitomycin-C-treated (45min, 75μg/ml)
CD40L-expressing ﬁbroblasts (a kind gift of Dr. T. Defrance,
Lyon, France) in the presence of 50U/ml IL2 and 100 ng/ml IL10.
Thereafter, the cells were cultured for 4 (Day 7) to 7 days (Day
10) without ﬁbroblasts, in the presence of IL2 (50U/ml), IL10
(100 ng/ml), and blocking anti-CD40L mAb (2μg/ml).
Generation of PBs and PCs by CpG2006 treatment in the
presence of IL15 or IL2 plus IL10 was performed as previously
described by Bernasconi et al. (2002). Brieﬂy, CD27+ B-cells were
cultured for up to 10 dayswith 3μg/mlCpGODN2006 plus either
100 ng/ml IL15 or 50U/ml IL2 and 100 ng/ml IL10. Proliferation
was monitored by PI staining.
IDENTIFICATION OF PLASMABLASTS AND PLASMA CELLS
Plasmablasts and PCs were identiﬁed by CD20, CD38, and
CD138 expression with a FACSCalibur ﬂow cytometer (Bec-
ton Dickinson), as previously described (Jego et al., 1999, 2001;
Geffroy-Luseau et al., 2008).
ISOLATION OF prePBs
Isolation of pre-plasmablast (prePBs) was performed as described
previously (Geffroy-Luseau et al., 2008). Brieﬂy,CD27B-cells were
cultured for 3 days with CD40L-expressing ﬁbroblasts in the pres-
ence of IL2 plus IL10 and then for 2 days with IL2 plus IL10 in the
presence of anti-CD40L mAb. At this time, the culture contained
prePBs (CD20+/−) and remaining B-cells (CD20++). To obtain
a pure population of prePBs engaged in differentiation, the B-cells
were removed with CD20 immunomagnetic beads by using a pos-
itive selection column (Column MS, Miltenyi), which selects only
highly labeled cells.
Ig SECRETION
IgG, IgA, and IgM secretion was determined by ELISA, as
previously described (Geffroy-Luseau et al., 2008).
WESTERN BLOTTING
Cells were pelleted and resuspended in lysis buffer (10mM Tris–
HCl pH= 7.6, 150mM NaCl, 5mM EDTA, 1mM PMSF, 2μg/ml
aprotinin, 1% Triton X100). After 40min on ice, lysates were
cleared by centrifugation at 10,000× g for 30min at 4˚C. Protein
concentration was measured using bicinchoninic acid (BCA Pro-
tein assay, Pierce, Rockford, IL, USA). Cleared lysates (70μg) were
separated by SDS-PAGE (12.5 or 15% acrylamide) and electro-
transferred to polyvinylidene diﬂuoride membranes. Western blot
analysiswas performedby standard techniqueswithECLdetection
(Pierce Perbio Science France, Brebières, France).
STIMULATION OF MYELOMA CELLS
Human myeloma cell lines (HMCLs) have been previously
described (Moreaux et al., 2011). Cells (500,000/ml) were cultured
for 2 days with or without CpG 2006 (5μg/ml) in the presence of
or without IL15 (100 ng/ml), as described previously (Jego et al.,
2006; Chiron et al., 2009). After culture, cells were stained with
anti-CD20-FITC or IgG1-FITC control mAb, and the ﬂuores-
cence was analyzed with a FACsCalibur ﬂow cytometer (Becton
Dickinson).
RESULTS
PBs AND PCs GENERATED IN THE PRESENCE OF CpG ODN REMAIN
CD20+
Because tonsil and bone marrow PCs display very different pheno-
types (CD20,CD138, Ig isotype),wewonderedwhether polyclonal
activation of memory B-cells through different mechanisms,
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CD40L stimulation versus CpG ODN stimulation, could promote
the generation of phenotypically different PCs. To answer this
question, CD27+ B-cells were puriﬁed from tonsils and activated
in the presence of IL2 and IL10 with either CD40L-expressing 3T6
ﬁbroblasts or with CpG2006. Because continuous activation of B-
cells by CD40L prevented differentiation (Figure 1A; Arpin et al.,
1995),we performed a transient coculture (3 days) followed by a 4-
to 7-day culture in the presence of anti-CD40L-blocking mAbs to
neutralize any remaining CD40L+ cells. In contrast to the CD40L
culture conditions, for CpG stimulation, the ligand was added at
Day 0 with no washes to remove CpG ODN. At Day 7, both cul-
tures displayed CD38+ PBs, conﬁrmed by morphology, but CpG
ODN-derived PBs were CD20+, albeit with diminished expres-
sion compared with the remaining CD20+CD38− B-cells, while
CD40L-derived PBs were markedly CD20− (Figure 1B). Of note,
at Day 10, both CD20+ and CD20+/− PCs expressed CD138, the
marker of PCs (Pellat-Deceunynck et al., 1994). However, the level
of CD138 expression was lower in CpG ODN-derived PCs than
in CD40L-derived PCs. We wondered whether these differences
in phenotype could be related to the presence of germinal cen-
ter B-cells, as CD27 is expressed by both germinal center B-cells
(CD27+CD38+) and memory B-cells (CD38−CD27+).Thus,we
puriﬁed CD27+ B-cells from the peripheral blood of healthy
donors, which only contains memory B-cells and not germinal
center B-cells. As shown in Figure 1C, peripheral CD27+ B-cells
also generated CD20+ PBs when activated with CpG ODN, show-
ing that this feature was not limited to tonsil CD27+ B-cells. To
quantify the level of expression of CD20 in both cultures at Day
7, we calculated the ratio of the levels of CD20 MFI of CD38+
cells (region 1) divided by the levels of CD20 MFI of CD38−
cells (region 2; four different tonsil samples and one peripheral
blood sample). The intensity of CD20 in the CD40L cultures was
of 0.0305± 0.0157, thus 3.6-fold lower compared with that of
CpG cultures, 0.1106± 0.0248 (n = 5, p = 0.0018, paired t -test;
Figure 1C right). Finally, CpG ODN-derived PCs displayed a phe-
notype similar to that of in situ tonsil PCs, which are CD20+
CD138+/− (Medina et al., 2002; Robillard et al., 2005). Cell cycle
analysis during the courses of differentiation did not show any
signiﬁcant differences between CD40L- and CpG ODN-generated
PBs (Figure 1D). In both cases, proliferation decreased similarly
during differentiation, and the incidence of subG1 peak increased
similarly to reach 45.7± 10.59 and 45± 12.70% of total cells, in
the CD40L and CpG culture, respectively (n = 3, p =NS paired
t -test). Because IL15has been shown tobe very efﬁcient at promot-
ing memory B-cell differentiation in the presence of CpG ODN
(Bernasconi et al., 2002), we wondered whether it could be more
or less efﬁcient than IL2+ IL10 in supporting the generation of
CD20+ PBs. As shown in Figure 1E, CpG ODN-generated PBs
(from peripheral or tonsil B-cells) showed similar levels of CD20
expression in the presence of IL2 and IL10 as they did in the
presence of IL15.
REMOVAL OR ADDITION OF CpG ODN DURING DIFFERENTIATION
MODULATED CD20 EXPRESSION
We next wondered whether CpG ODN could directly modulate
CD20 expression. To test this, we remove CpG ODN from CpG
ODN-stimulated B-cells on day 3. As shown in Figure 2A, removal
of CpG ODN slightly increased the proportion of cells with lower
CD20 from 46± 5 to 64± 7%, compared with 65± 12% for
the CD40L culture. The CD20 intensity was slightly decreased
too from 0.094± 0.010 to 0.055± 0.010 (n = 3, p = 0.026), but
it still remained around twofold higher than that of CD40L-
drivenPCs (0.030± 0.010,p = 0.085). Reciprocally,we addedCpG
ODN to puriﬁed prePBs engaged in the differentiation process
after transient CD40 activation. The remaining CD20+ B-cells
were depleted 2 days after CD40L removal (Day 5) in order
to target only prePBs and to exclude any recruitment of “rest-
ing” CD20+ B-cells (Geffroy-Luseau et al., 2008). As shown in
Figure 2B, the addition of CpG ODN slightly increased the pro-
portion of CD38+CD20+ cells from 3.9± 0.27 to 15.25± 1.51%
at day 10, n = 3, p = 0.0015 (Figure 2B right, upper panel). In
the CpG culture, CD20+CD38+ cells were only partly CD138+,
with 7% of cells being CD20+CD138+ and 12% of cells being
CD20+CD138−, compared with 2 and 2% in the culture without
CpG, respectively (illustrated in Figure 2B left). The proportion
of CD138+CD20+ cells was higher in the culture with CpG,
7.2± 0.7%, compared with the culture without CpG, 3.6± 0.9%,
p = 0.073 (Figure 2B right, lower panel). Thus, although CpG
increased the proportion of CD20+ PBs and PCs, it did not
prevent the appearance of CD20− PBs and CD20− PCs. These
results suggest that CpG ODN, in contrast to CD40L, increased
the survival of CD20+ PBs.
MODULATION OF PROLIFERATION AND SURVIVAL PROTEINS IS
SIMILAR IN CD40L- AND CpG ODN-GENERATED PBs AND PCs
B-cell differentiation requires the concomitant regulation of both
survival and proliferation (Chen-Kiang, 2003; Vikstrom and Tar-
linton, 2011). Among all Bcl-2 family molecules, Bim, Mcl-1, and
Bcl-2 are three major regulators of B-cell and PC survival (Puthier
et al., 1999; Vikstrom and Tarlinton, 2011). CDK inhibitors, espe-
cially p18, are required for PC generation (Chen-Kiang, 2003).
We wondered whether CD40L and CpG ODN differentially mod-
ulated the expression of these molecules. Tonsil CD27+ B-cells
(Day 0) were cultured either with IL2/IL10/CpG ODN for 7 days
or with IL2/IL10/CD40L for 3 days (Day 3) followed by 2 days
with IL2/IL10, after which CD20+/− prePBs and CD20+ B-cells
were puriﬁed (Day 5). PrePBs were cultured for an additional
2 days in the presence of IL2 and IL10 (Day 7). Cells were then
collected and lysed, and protein expression was analyzed by west-
ern blot at the indicated times (Figure 3). Upon CD40L or CpG
ODN stimulation, expression of all three isoforms of Bim, Mcl-
1 full length (FL), Bcl-xL, PCNA, and survivin increased, while
the expression of Bcl-2, p27 (Kip1), and p18 (INK4c) decreased
(Day 3). Modulation of Bcl-2, PCNA, p27, and p18 was in agree-
ment with the proliferation increase. Once CD27+ B-cells entered
cell cycle induced by either CD40L or CpG, they switched from a
Bcl-2 expression toward a Mcl-1 and Bcl-xL expression suggest-
ing that cycling CD27+ B-cells should be rather Mcl-1/Bim or
Bcl-xL/Bim than Bcl-2/Bim primed for death. During subsequent
differentiation, Bim expression remained high, Mcl-1 FL expres-
sion decreased, levels of the pro-apoptotic Mcl-1 cleaved form
C1 increased (Ménoret et al., 2010), Bcl-xL expression remained
high while Bcl-2 expression remained low. Although Bcl-2 expres-
sion was stronger in CpG ODN-stimulated PBs/PCs than in
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FIGURE 1 | (A) Continuous stimulation of CD27+ B-cells with
CD40L-expressing ﬁbroblasts prevented PC generation. CD27+ B-cells
were puriﬁed from the tonsils of healthy donors, as described previously
(Geffroy-Luseau et al., 2008 and Materials and Methods). B-cells
(800,000 cells/ml) were cultured for 3 days with CD40L-expressing
ﬁbroblasts in the presence of IL2 and IL10 and harvested and cultured
again for 4 days with CD40L-expressing ﬁbroblasts in the presence of IL2
and IL10. The phenotype of the cells (CD20, CD38) was assessed by
double staining. Representative experiment out of three. (B) Comparison
of PCs generated from CD27+ B-cells either activated with
CD40L-expressing ﬁbroblasts or cultured in the presence of CpG2006.
B-cells (800,000 cells/ml) from the same donor were either cultured for
3 days with CD40L-expressing ﬁbroblasts and then cultured for 4 (Day 7)
to 7 (Day 10) days with IL2 plus IL10 in the presence of blocking
anti-CD40L mAb or cultured for 7–10 days in the continuous presence of
CpG2006 (3μg/ml) and IL2 plus IL10. The phenotype of the cells (CD20,
CD38, CD138) was assessed by double or triple staining as indicated in
the ﬁgure. May–Grünwald Giemsa staining of cells cultured for 7 days
with CpG ODN plus IL2 and IL10 showed a typical PB morphology
(eccentrically shaped nucleus and relatively abundant basophilic
cytoplasm with archoplasm). The data represent the result of a
representative experiment performed with one tonsil (three others were
performed with three other independent donors). (C) Comparison of PCs
generated from tonsil or peripheral blood CD27+ B-cells cultured in the
presence of CpG2006. CD27+ B-cells (D0) were cultured as described in
(B), and their phenotypes were analyzed at Day 7. Region 1 delineates
CD38+CD20dim/− PBs, and region 2 delineates CD38−CD20+ B-cells.
Right: the relative CD20 intensity in PBs at Day 7 was expressed as the
ratio representative of CD20 MFI in CD38+ PBs (region 1) divided by the
CD20 MFI of the remaining B-cells CD20+CD38− (region 2). Five
independent experiments were performed with CD27+ B-cells puriﬁed
from four tonsils and one peripheral blood sample. (D) Cell cycle analysis
of the differentiation of CD27+ B-cells cultured as described in (B).
Histograms represent the proportion of cells in the subG1, G1, S, and
G2M phases. SubG1 proportion was deﬁned on the whole population. For
G1, S, and G2M phases, the proportion was deﬁned after exclusion of
subG1 peak (Modﬁt). The data represent the mean±SD of three
independent experiments performed with three independent donors. (E)
Comparison of CD20+ PB generation after CpG2006 stimulation in the
presence of IL2 plus IL10 or IL15. CD27+ B-cells (tonsil or peripheral
blood) were cultured as described in the legend of Figure 1B, with IL2
plus IL10 or with IL15. The phenotypes of the PBs were analyzed at Day 7.
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FIGURE 2 | (A) Removal of CpG ODN decreased the appearance of
CD20+ PBs. Left: CD27+ B-cells from a tonsil were cultured with IL2 plus
IL10 in the CD40L model (upper panel), with CpG2006 for 7 days (middle
panel) or with CpG2006 for 4 days and then washed and cultured for
3 days without CpG (lower panel). The phenotype was analyzed at Day 7.
The intensity of CD20 on PBs was expressed as the ratio (r ) of MFI
staining on CD38+ cells (region 1) divided by CD38− cells (region 2).
Representative experiment out of 3. Right: data represent the mean±SD
of three independent experiments performed with three independent
donors. (B) Addition of CpG ODN to CD40L-activated B-cells increased the
appearance of CD20+ PBs. CD27+ B-cells from three independent
donors were cultured for 3 days with CD40L-expressing ﬁbroblasts in the
presence of IL2 plus IL10 and then for 2 days with IL2 plus IL10 in the
presence of anti-CD40L mAb. The remaining CD20++ B-cells were
removed to obtain a pure population of prePB cells engaged in
differentiation (see Materials and Methods). PrePBs (Day 5) were then
cultured in the presence of IL2 plus IL10 with or without CpG2006. The
CD20 phenotype of PBs and PCs was analyzed 2 (Day 7) to 5 (Day
10) days after in double or triple staining. Representative experiment out
of three. Right: data represent the proportion at Day 10 of CD20+ (upper
panel) and of CD20+CD138+ (lower panel) in the culture with or without
CpG (data represent the mean±SD of three independent experiments).
CD20−/CD40L-stimulated cells, no conclusion could be reached
because the CpG ODN culture still contained B-cells, while the
CD40L culture contained only PBs/PCs. Survivin and PCNA dis-
played regulation similar to that of Mcl-1, increasing up to Day
5 and then decreasing. At Days 6 and 7, p27 expression remained
low compared with unstimulated B-cells, but p18 expression was
strongly increased, consistent with previous reports regarding
expression of these factors during growth arrest and PC generation
(Chen-Kiang, 2003). At Days 6 and 7, the decreased expression of
anti-apoptotic proteins Mcl-1 and Bcl-2 and the increased levels
of the Mcl-1-C1 form were in agreement with the high incidence
of apoptosis in these cultures, as indicated by the strong cleavage
of caspase 3 (Jego et al., 1999, 2001). In summary, CD40L- or CpG
ODN-generated PBs/PCs displayed a similar expression pattern
of molecules involved in both the survival/apoptotic and cell cycle
pathways.
CpG ODN INCREASED THE SECRETION OF IgM
Bernasconi et al. (2002) have compared the proliferation and
differentiation of switched (IgG, IgA) and non-switched (IgM)
memory B-cells in response to either CpG ODN or bystander T-
cell help. They showed that bystander T-cell help preferentially
induced the proliferation of switched B-cells, while CpG ODN
preferentially induced the proliferation of non-switched B-cells.
Because the differentiation of B-cells into PCs is linkedwith prolif-
eration, we theorized that CpG ODN should favor IgM secretion,
while CD40L should favor secretion of IgG and IgA. Thus, we
measured Ig secretion in the IL2/IL10 CD40L and CpG ODN/IL15
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FIGURE 3 | Comparison of the expression profile of molecules
controlling cell cycle and survival during PC generation.Tonsil CD27+
B-cells (Day 0) from two independent donors were cultured as described in
Figure 1B. In the CD40L culture, prePBs (CD20− Day 5) were puriﬁed as
described in Figure 2B and further cultured for 2 days with IL2 and IL10
(Day 7). Cells were lysed and lysates were equally divided in two samples.
The same amount of proteins was loaded per lane and proteins were
resolved by SDS-PAGE in two twin gels (i.e., two twin gels for the CD40L
samples and two twin gels for the CpG samples). Western blot analysis
was performed as described previously (Puthier et al., 1999; Ménoret et al.,
2010). Membranes were probed, stripped, and reprobed with the antibodies
in the order presented in the ﬁgure (Actin as last). EL, Bim extra large; L,
large; S, small; Mcl-1 FL, Mcl-1 full length; Mcl-1 C1, Mcl-1 cleaved form
C1; p17, caspase 3 cleaved form. Representative experiment out of two.
cultures. Compared with the IL2/IL10/CD40L culture, the CpG
ODN/IL15 culture showed increased secretion of IgA (1.3- to 1.4-
fold-increase), IgG (1.45- to 1.56-fold-increase) and, importantly,
IgM (2.02–7.22), as shown inFigure 4A. To assess the effect of CpG
ODNon the sameprePBs,we cultured IL2/IL10/CD40L-generated
FIGURE 4 | (A) Ig secretion of CD27+ B-cells cultured with CD40L plus IL2
and IL10 or with CpG ODN plus IL15. CD27+ B-cells from tonsil (T) or
peripheral blood B were cultured as described in the legend of Figure 1.
Supernatants were collected at Day 10, and Ig secretion was assessed by
ELISA. (B) Ig secretion of CD40L-generated prePBs cultured with or without
CpG ODN. PrePBs generated in the CD40L culture were obtained as
described in Figure 2B and cultured for 3 days with or without CpG in the
presence of IL2+ IL10. Supernatants were collected at Day 7, and Ig
secretion was assessed by ELISA. Three independent experiments were
performed with two tonsils.
prePBs (Day 5) with or without CpG ODN for 2 days. As shown in
Figure 4B, addition of CpG ODN signiﬁcantly altered Ig secretion
by increasing the secretion of IgM (median value 177%) and IgA
(median value 129%) while decreasing that of IgG (median value
90%),p = 0.0176ANOVA test. These data collectively indicate that
IgM secretion was increased in the presence of CpG ODN, sug-
gesting that CpG ODNs were more able than CD40L to induce the
generation of IgM-secreting PCs.
CpG ODN DID NOT INDUCE CD20 EXPRESSION IN MYELOMA CELL LINES
In humans, the archetype of malignant PCs is MM. MM is marked
by the presence of a malignant clone secreting a monoclonal pro-
tein, often IgA or IgG and, very rarely, IgM (Kyle and Rajkumar,
2008). Myeloma cells are thought to be the malignant counterpart
of bone marrow PCs. Similar to bone marrow PCs, MM cells are
mainly CD20− (Robillard et al., 2003; Bataille et al., 2006). MM
cells have been shown to express TLR9 and to respond to CpG
ODN by increased proliferation and survival (Bohnhorst et al.,
2006; Jego et al., 2006). In chronic lymphoid leukemia, a CD20+
neoplasm, CpG ODN was shown to increase the level of CD20
expression after 24–48 h (Mankaï et al., 2009). To assess whether
CpG ODN could induce or increase CD20 expression in myeloma
cells, eight TLR9+CD20−HMCLs,BCN, JIM3,MDN,NCI-H929,
RPMI8226, SBN, U266 and XG6, and one TLR9+CD20+ HMCL,
Karpas 620,were cultured for 2 dayswith 5μg/mlCpGODN2006.
As shown inFigure 5,CpGODNneither inducedCD20 expression
in CD20−TLR9+ HMCLs nor increased it in the CD20+TLR9+
HMCL. These data show that CpG ODN did not modulate CD20
expression in malignant IgG or IgA PCs.
DISCUSSION
In this paper, we show that CpG ODN and CD40L induce
PBs and PCs with different features. Indeed, while CD40L
promotes the generation of “classical” CD20−CD138− PBs
and CD20−CD138+ PCs, CpG ODN promotes that of
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FIGURE 5 | CpG ODN neither induce nor increase CD20 expression on myeloma cell lines. Nine multiple myeloma cell lines expressingTLR9 were cultured
for 2 days with or without CpG2006, and CD20 expression was analyzed by ﬂow cytometry. Overlay histograms represent the CD20 staining over the control
staining.
CD20+CD38+CD138+/−PBs/PCs andCD20−CD38+CD138+
PCs. This CD20+CD38+CD138+/− phenotype, which is not
reminiscent of any B to PC intermediates (Pellat-Deceunynck
et al., 1994; Arpin et al., 1997; Jego et al., 1999, 2001; Medina
et al., 2002; Odendahl et al., 2005; Robillard et al., 2005; Geffroy-
Luseau et al., 2008; Jourdan et al., 2011), rather looks like to that
of tonsil PCs (Medina et al., 2002; Robillard et al., 2005). It seems
unlikely that CD20+ PCs could have emerged from CD27− cells
because they represented a very weak contaminating population
and because CpG ODN are not able to induce PC generation from
CD27− B-cells unless anti-Ig are added (Bernasconi et al., 2002).
The addition of CpG ODN to CD40L-induced prePBs increased
the proportion of CD20+ PBs and modiﬁed the Ig secretion iso-
type. It seems unlikely that CpG ODN simply increased CD20
expression because PBs obtained after the addition of CpG ODN
were mainly CD20−. Our results collectively suggest that CpG
ODN, which induced the proliferation of CD27+ memory B-
cells, increased the survival of either CD20+ prePBs/PBs or both.
Reciprocally, the removal of CpG ODN from CpG ODN induced
prePBs decreasedCD20 expression onPBs. This later result further
suggests that CD20+ PBs have impaired survival without TLR9
stimulation. Analysis of proliferation and expression of proteins
involved in proliferation, such as PCNA, did not demonstrate sig-
niﬁcant global differences between the two types of stimulation
(Figures 1 and 3), arguing against a role of CpG in proliferation
of CD20+CD38+CD138+/− cells. In the CD40L culture, CD40L
was removed after 3 days because CD40L is known to block PC
generation by inducing continuous B proliferation (Arpin et al.,
1995). Interestingly, in contrast to CD40L, CpG ODN induced the
proliferation of B-cells but did not block their subsequent differen-
tiation. Because CpG ODN did not maintain proliferation, and its
addition or removal subsequently impacted CD20 expression, we
might conclude that it favored the survival of someCD20+ prePBs
orCD20+PBs. Jourdan et al. (2009) reported that, although IgM+
activated B-cells represented the major population of cycling B-
cells after transient culture with soluble CD40L and CpG ODN,
IgM+ PBs and PCs represented only a minor population, suggest-
ing that either IgM PBs did not survive, in contrast to IgG PBs, or
that IgM cycling B-cells were unable to differentiate into PBs in the
absence of CpG ODN. Addition of CpG ODN to CD40L prePBs
modiﬁed the Ig secretion (increase of IgM). Our data are in agree-
ment with those of Bernasconi et al. (2002) who reported that
CpG ODN and CD40L do not equally activate non-switched and
switchedCD27+B-cells: IgM+CD27+B-cells efﬁciently respond
to CpG ODN but not to CD40L in contrast to switched CD27+
B-cells, which do equally respond to both stimulations.
In malignant and normal B-cells, CpG ODN increase CD20
expression at both protein andmRNA levels but themechanism(s)
are not known (Jahrsdörfer et al., 2001; Mankaï et al., 2009).
The effect of CpG ODN is more difﬁcult to analyze in our study
because cells differentiate and loose their CD20 phenotype during
this process. Thus, CpG ODN either stimulate a subpopulation
www.frontiersin.org December 2011 | Volume 2 | Article 83 | 7
Geffroy-Luseau et al. CpG ODN generates CD20+ plasma cells
of CD27+ B-cells (IgM+?) committed to become CD20+ PBs
and PCs or maintain CD20 expression on the PBs and PCs, which
loose CD20 expression during their generation. Further experi-
ments performed with cells isolated along all the differentiation
process from pure switched and non-switched CD27+ B-cells are
required to reach a deﬁnitive conclusion concerning the precise
role of CpG ODN.
In vivo, CD20+ PBs and PCs are found in tonsils, not within
the bone marrow (Medina et al., 2002). PCs from tonsils express a
low level of CD138 in contrast to PCs from bone marrow (Medina
et al., 2002; Robillard et al., 2005). Thus, based on the pheno-
type, CD20+CD138+/− cells obtained with CpG ODN look like
to tonsil PCs. In humans, PCs are also found in the lamina pro-
pria, in spleen and lymph nodes, and in the rheumatoid synovium
(Dechanet et al., 1995; Medina et al., 2002; Moser et al., 2006;
Radbruch et al., 2006). In humans, the phenotype of PCs has been
mainly studied in tonsils and bone marrow, not in spleen or lymph
nodes. To date, only tonsil PCs have been reported to express
CD20. The CD20+CD38+CD138+/− phenotype of tonsil PCs
does not correlate with an intermediate stage of differentiation
because CD20 expression is lost before CD138 appearance (Jego
et al., 1999, 2001; Odendahl et al., 2005). Thus, there is to date no
obvious explanation for the particular phenotype of tonsil PCs.
Because, tonsillectomies are performed in children and teenagers
with recurrent bacterial infections of tonsils, it is possible that
the CD20+ phenotype of PCs might be related to the recurrent
infections rather than to the tonsilar location. Further analysis
of phenotype in various lymphoid organs (tonsil, spleen, lymph
node) in the absence of recurrent bacterial infections could deter-
mine whether this CD20+ phenotype is related to infections or to
location, or both.
Although TLRs are widely expressed on malignant B-cells,
there is no evidence to date that chronic activation of B-cells is
involved in the emergence or growth or survival of malignant B-
cells in vivo. MM and WM (Waldenstrom macroglobulinemia)
are two PC malignancies characterized by a monoclonal peak of
immunoglobulin of IgG, (or IgA), or IgM isotype, respectively;
however, in contrast to MM cells that are mainly located within
the bonemarrow,WMcells aremainly foundwithin the spleen and
lymph nodes (Chng et al., 2006; Kyle and Rajkumar, 2008; Ban-
wait et al., 2011). MM cells exhibit all the hallmarks of Ag-selected
switched B-cells, while WM cells exhibit those of Ag-selected non-
switched B-cells (Martín-Jiménez et al., 2007). In contrast to MM
cells,WM cells are a mix of lymphoid (CD19+ CD20+ CD138−)
and lymphoplasmacytic cells (CD19+ CD20+ CD138+/−; Chng
et al., 2006; Hodge et al., 2011). It would be of particular interest
to establish and compare the gene expression proﬁles of WM cells,
tonsil PCs and CpG ODN-derived CD20+ PBs/PCs.
Plasmablasts and PCs, which are highly susceptible to apopto-
sis, are primed for death by the expression of BH3-only molecules
of the Bcl-2 family (Jego et al., 1999; Vikstrom and Tarlinton,
2011). Only interactions with the local microenvironment, which
might include osteoclasts, can rescue them from death, explaining
the long-life of resident bone marrow PCs (Odendahl et al., 2005;
Moser et al., 2006; Geffroy-Luseau et al., 2008). In vitro, the gen-
eration of PBs and PCs from B-cells is always marked by a high
incidence of apoptosis, as shown by the high incidence of cells in
subG1 peak (Figure 2D and Jego et al., 1999, 2001). In this study,
we show that apoptosis may be explained by the cleavage of Mcl-1
and the activation of caspase 3. Activation of B-cells induces an
increase of Mcl-1, Bcl-xL, and Bim and a decrease of Bcl-2, sug-
gesting that PBs and PCs should be rather Mcl-1 or Bcl-xL primed
for death while resting memory B-cells should be rather Bcl-2
primed for death (Figure 3 and Vikstrom and Tarlinton, 2011).
The modulation of expression of these molecules was very similar
in both CD40L and CpG cultures, showing that it is an intrinsic
feature of PBs and PCs. In summary, we have shown that CpG
ODN induced the in vitro generation of CD20+ PBs and CD20+
PCs from CD27+ memory B-cells.
ACKNOWLEDGMENTS
Supported by the Ligue Nationale Contre Le Cancer (Equipe label-
lisée 2008). The authors thank Pr. R. Bataille and Dr. N. Robillard
for their critical review of the manuscript.
REFERENCES
Arpin, C., Banchereau, J., and Liu, Y. J.
(1997) Memory B cells are biased
towards terminal differentiation: a
strategy that may prevent repertoire
freezing. J. Exp. Med. 186, 931–940.
Arpin, C., Déchanet, J., Van Kooten, C.,
Merville, P., Grouard, G., Brière, F.,
Banchereau, J., and Liu, Y. J. (1995).
Generation of memory B cells and
plasma cells in vitro. Science 268,
720–722.
Banwait, R., O’Regan, K., Campigotto,
F., Harris, B., Yarar, D., Bagshaw,
M., Leleu, X., Leduc, R., Ramaiya,
N., Weller, E., and Ghobrial, I.
M. (2011). The role of 18F-FDG
PET/CT imaging in Waldenstrom
macroglobulinemia. Am. J. Hematol.
86, 567–572.
Bataille, R., Jégo, G., Robillard, N.,
Barillé-Nion, S., Harousseau, J.
L., Moreau, P., Amiot, M., and
Pellat-Deceunynck, C. (2006). The
phenotype of normal, reactive and
malignant plasma cells. Identiﬁ-
cation of “many and multiple
myelomas” and of new targets for
myeloma therapies. Haematologica
91, 1234–1240.
Bernasconi, N. L., Traggiai, E., and Lan-
zavecchia, A. (2002). Maintenance
of serological memory by polyclonal
activation of humanmemoryB cells.
Science 298, 2199–2202.
Bohnhorst, J., Rasmussen, T., Moen, S.
H., Flottum,M.,Knudsen, L., Borset,
M., Espevik, T., and Sundan, A.
(2006). Toll-like receptors mediate
proliferation and survival of mul-
tiple myeloma cells. Leukemia 20,
1138–1144.
Chen-Kiang, S. (2003). Cell-cycle con-
trol of plasma cell differentiation
and tumorigenesis. Immunol. Rev.
194, 39–47.
Chiron, D., Pellat-Deceunynck, C.,
Maillasson, M., Bataille, R., and
Jego, G. (2009). Phosphorothioate-
modiﬁed TLR9 ligands protect
cancer cells against TRAIL-
induced apoptosis. J. Immunol. 183,
4371–4377.
Chng, W. J., Schop, R. F., Price-Troska,
T., Ghobrial, I., Kay, N., Jelinek, D.
F., Gertz, M. A., Dispenzieri, A.,
Lacy, M., Kyle, R. A., Greipp, P.
R., Tschumper, R. C., Fonseca, R.,
and Bergsagel, P. L. (2006). Gene-
expression proﬁling of Waldenstrom
macroglobulinemia reveals a pheno-
type more similar to chronic lym-
phocytic leukemia than multiple
myeloma. Blood 108, 2755–2763.
De Vos, J., Hose, D., Reme, T., Tarte, K.,
Moreaux, J., Mahtouk, K., Jourdan,
M.,Goldschmidt,H.,Rossi, J. F.,Cre-
mer, F. W., and Klein, B. (2006).
Microarray-based understanding of
normal and malignant plasma cells.
Immunol. Rev. 210, 86–104.
Dechanet, J., Merville, P., Durand,
I., Banchereau, J., and Miossec,
P. (1995). The ability of synovio-
cytes to support terminal differ-
entiation of activated B cells may
explain plasma cell accumulation
in rheumatoid synovium. J. Clin.
Invest. 95, 456–463.
Geffroy-Luseau, A., Jégo, G., Bataille,
R., Campion, L., and Pellat-
Deceunynck, C. (2008). Osteoclasts
support the survival of human
plasma cells in vitro. Int. Immunol.
20, 775–782.
Hodge, L. S., Novak, A. J., Grote, D.
M., Braggio, E., Ketterling, R. P.,
Manske, M. K., Price Troska, T. L.,
Frontiers in Immunology | B Cell Biology December 2011 | Volume 2 | Article 83 | 8
Geffroy-Luseau et al. CpG ODN generates CD20+ plasma cells
Ziesmer, S. C., Fonseca, R.,Witzig, T.
E., Morice, W. G., Gertz, M. A., and
Ansell, S. M. (2011). Establishment
and characterization of a novel
Waldenstrom macroglobulinemia
cell line, MWCL-1. Blood 117,
e190–197.
Jahrsdörfer,B.,Hartmann,G.,Racila, E.,
Jackson, W., Mühlenhoff, L., Mein-
hardt, G., Endres, S., Link, B. K.,
Krieg, A. M., and Weiner, G. J.
(2001). CpG DNA increases pri-
mary malignant B cell expression of
costimulatory molecules and target
antigens. J. Leukoc. Biol. 69, 81–88.
Jego, G., Bataille, R., Geffroy-Luseau,
A., Descamps, G., and Pellat-
Deceunynck, C. (2006). Pathogen-
associated molecular patterns are
growth and survival factors for
human myeloma cells through
toll-like receptors. Leukemia 20,
1130–1137.
Jego, G., Bataille, R., and Pellat-
Deceunynck, C. (2001). Interleukin-
6 is a growth factor for nonmalig-
nant human plasmablasts. Blood 97,
1817–1822.
Jego, G., Robillard, N., Puthier, D.,
Amiot, M., Accard, F., Pineau, D.,
Harousseau, J. L., Bataille, R., and
Pellat-Deceunynck, C. (1999). Reac-
tive plasmacytoses are expansions
of plasmablasts retaining the capac-
ity to differentiate into plasma cells.
Blood 94, 701–712.
Jourdan, M., Caraux, A., Caron, G.,
Robert, N., Fiol, G., Rème, T., Bol-
loré, K., Vendrell, J. P., Le Gallou, S.,
Mourcin, F., De Vos, J., Kassambara,
A., Duperray, C., Hose, D., Fest, T.,
Tarte, K., and Klein, B. (2011). Char-
acterizationof a transitional preplas-
mablast population in the process of
human B cell to plasma cell differen-
tiation. J. Immunol. 187, 3931–3941.
Jourdan, M., Caraux, A., De Vos, J.,
Fiol, G., Larroque, M., Cognot, C.,
Bret, C., Duperray, C., Hose, D.,
and Klein, B. (2009). An in vitro
model of differentiation of mem-
ory B cells into plasmablasts and
plasma cells including detailed phe-
notypic and molecular characteriza-
tion. Blood 114, 5173–5181.
Kyle, R. A., and Rajkumar, S. V.
(2008). Multiple myeloma. Blood
111, 2962–2972.
Mankaï, A., Buhé, V., Hammadi, M.,
Youinou, P., Ghedira, I., Berthou, C.,
and Bordron, A. (2009). Improve-
ment of rituximab efﬁciency in
chronic lymphocytic leukemia by
CpG-mediated upregulation of
CD20 expression independently of
PU.1. Ann. N. Y. Acad. Sci. 1173,
721–728.
Martín-Jiménez, P., García-Sanz, R.,
Balanzategui,A.,Alcoceba,M.,Ocio,
E., Sanchez, M. L., González, M.,
and San Miguel, J. (2007). Molecu-
lar characterization of heavy chain
immunoglobulin gene rearrange-
ments in Waldenström’s macroglob-
ulinemia and IgM monoclonal gam-
mopathy of undetermined signiﬁ-
cance. Haematologica 92, 635–642.
Medina, F., Segundo, C., Campos-Caro,
A.,Gonzalez-Garcia, I., and Brieva, J.
A. (2002). The heterogeneity shown
by human plasma cells from ton-
sil, blood, and bone marrow reveals
graded stages of increasing matu-
rity, but local proﬁles of adhe-
sion molecule expression. Blood 99,
2154–2161.
Ménoret, E., Gomez-Bougie, P., Sur-
get, S., Trichet, V., Oliver, L.,
Pellat-Deceunynck, C., and Amiot,
M. (2010). Mcl-1128-350 fragment
induces apoptosis through direct
interaction with Bax. FEBS Lett. 584,
487–492.
Moreaux, J., Klein, B., Bataille, R.,
Descamps, G., Maïga, S., Hose, D.,
Goldschmidt,H., Jauch,A.,Rème,T.,
Jourdan, M., Amiot, M., and Pellat-
Deceunynck, C. (2011). A high-risk
signature for patients with multi-
ple myeloma established from the
molecular classiﬁcation of human
myeloma cell lines. Haematologica
96, 574–582.
Moser, K., Tokoyoda, K., Radbruch, A.,
MacLennan, I., and Manz, R. A.
(2006). Stromal niches, plasma cell
differentiation and survival. Curr.
Opin. Immunol. 18, 265–270.
Odendahl, M., Mei, H., Hoyer, B. F.,
Jacobi, A. M.,Hansen,A.,Muehling-
haus, G., Berek, C., Hiepe, F., Manz,
R., Radbruch, A., and Dörner, T.
(2005). Generation of migratory
antigen-speciﬁc plasma blasts and
mobilization of resident plasma cells
in a secondary immune response.
Blood 105, 1614–1621.
Pellat-Deceunynck, C., Bataille, R.,
Robillard, N., Harousseau, J. L.,
Rapp, M. J., Juge-Morineau, N.,Wij-
denes, J., and Amiot, M. (1994).
Expression of CD28 and CD40 in
human myeloma cells: a compara-
tive study with normal plasma cells.
Blood 84, 2597–2603.
Puthier, D., Pellat-Deceunynck, C., Bar-
illé, S., Robillard, N., Rapp, M.
J., Juge-Morineau, N., Harousseau,
J. L., Bataille, R., and Amiot, M.
(1999). Differential expression of
Bcl-2 in human plasma cell disor-
ders according to proliferation sta-
tus and malignancy. Leukemia 13,
289–294.
Radbruch, A., Muehlinghaus, G., Luger,
E. O., Inamine, A., Smith, K. G.,
Dorner, T., and Hiepe, F. (2006).
Competence and competition: the
challenge of becoming a long-lived
plasma cell. Nat. Rev. Immunol. 6,
741–750.
Robillard, N., Avet-Loiseau,H., Garand,
R., Moreau, P., Pineau, D., Rapp,
M. J., Harousseau, J. L., and
Bataille, R. (2003). CD20 is asso-
ciated with a small mature plasma
cell morphology and t(11;14) in
multiple myeloma. Blood 103,
1070–1071.
Robillard, N., Pellat-Deceunynck, C.,
and Bataille, R. (2005). Pheno-
typic characterization of the human
myeloma cell growth fraction. Blood
105, 4845–4848.
Shapiro-Shelef, M., and Calame, K.
(2005). Regulation of plasma-cell
development. Nat. Rev. Immunol. 5,
230–242.
Vikstrom, I., and Tarlinton, D. M.
(2011). B cell memory and the role
of apoptosis in its formation. Mol.
Immunol. 48, 1301–1306.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 14 October 2011; accepted: 11
December 2011; published online: 30
December 2011.
Citation: Geffroy-Luseau A, Chiron D,
Descamps G, Jégo G, Amiot M and
Pellat-Deceunynck C (2011)TLR9 ligand
induces the generation of CD20+ plas-
mablasts and plasma cells from CD27+
memory B-cells. Front. Immun. 2:83. doi:
10.3389/ﬁmmu.2011.00083
This article was submitted to Frontiers in
B Cell Biology, a specialty of Frontiers in
Immunology.
Copyright © 2011 Geffroy-Luseau, Chi-
ron, Descamps, Jégo, Amiot and Pellat-
Deceunynck. This is an open-access arti-
cle distributed under the terms of the Cre-
ative Commons Attribution Non Com-
mercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided the
original authors and source are credited.
www.frontiersin.org December 2011 | Volume 2 | Article 83 | 9
